| Symbol | BRTX |
|---|---|
| Name | BIORESTORATIVE THERAPIES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Managed Health Care |
| Address | 40 MARCUS DRIVE, MELVILLE, New York, 11747, United States |
| Telephone | +1 631 760-8100 |
| Fax | — |
| — | |
| Website | https://www.biorestorative.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001505497 |
| Description | BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The companys two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patients bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. Additional info from NASDAQ: |
(99% Neutral) BIORESTORATIVE THERAPIES, INC. (BRTX) Announces Executive Departure
Read moreNew Form 8-K/A - BioRestorative Therapies, Inc. <b>Filed:</b> 2026-09-10 <b>AccNo:</b> 0001213900-26-098820 <b>Size:</b> 215 KB <br />Item 4.01: Changes in Registrant's Certifying Accountant <br />Item 8.01: Other Events <br />Item 9.01: Financial Statements and Exhibits
Read more(99% Neutral) BIORESTORATIVE THERAPIES, INC. (BRTX) Announces Clinical Development Update
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Deficient and Delinquent.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Deficient and Delinquent.
Read more(99% Neutral) BIORESTORATIVE THERAPIES, INC. (BRTX) Announces Update on Collaboration with Common Stock
Read moreNew Form SCHEDULE 13G/A - BioRestorative Therapies, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001094891-26-000263 <b>Size:</b> 6 KB
Read moreNew Form 3 - BioRestorative Therapies, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001213900-26-083461 <b>Size:</b> 3 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04042844 | A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) | Phase2 | Lumbar Disc Disease | Recruiting | 2022-06-30 | 2027-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Saline | Other | Phase PHASE2 | Lumbar Disc Disease | RECRUITING | NCT04042844 |
| BRTX-100 | Other | Phase PHASE2 | Lumbar Disc Disease | RECRUITING | NCT04042844 |